Democrats are seeking to make in-vitro fertilization an election issue, with Vice President Kamala Harris declaring during ...

Issuers still hold the key role in fighting fraud without compromising customer experience. A proactive issuer strategy ...

BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by ...

For the primary endpoint of AGV at Week 52, children treated with TransCon CNP (n=57) demonstrated an LS mean AGV of 5.89 ...

Check the time stamp on this data. Updated AI-Generated Signals for Centerpoint Energy Inc (holding Co) (CNP) available here: ...

Copenhagen-based Ascendis designed the trial to compare its once-weekly prodrug of C-type natriuretic peptide (CNP) to ...

The machinations of a powerful syndicate behind the success of school choice makes for a juicy story. Too bad it isn’t true.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ascendis' TransCon CNP showed similar efficacy to BioMarin's Voxzogo but offers once-weekly dosing. Learn more on BMRN and ...

(RTTNews) - Ascendis Pharma A/S (ASND) Monday said the pivotal ApproaCH study of TransCon CNP, in children with achondroplasia met its primary goal. The company's shares were more than 17 percent up ...

Analyst Paul Choi of Goldman Sachs maintained a Buy rating on Ascendis Pharma (ASND – Research Report), boosting the price target to ...

BioMarin Pharmaceutical (NASDAQ:BMRN) is down ~17% Monday following positive data from an Ascendis Pharma ...